State of New Jersey Common Pension Fund D Has $2.03 Million Holdings in Prestige Consumer Healthcare Inc. $PBH

State of New Jersey Common Pension Fund D raised its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 46.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 32,499 shares of the company’s stock after purchasing an additional 10,343 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Prestige Consumer Healthcare were worth $2,028,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in PBH. Allspring Global Investments Holdings LLC grew its stake in shares of Prestige Consumer Healthcare by 4.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after buying an additional 70,376 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in Prestige Consumer Healthcare in the third quarter worth approximately $1,890,000. AXQ Capital LP bought a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $694,000. Tributary Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 157.3% during the 3rd quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after purchasing an additional 231,969 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Prestige Consumer Healthcare by 51.8% in the 2nd quarter. Franklin Resources Inc. now owns 33,476 shares of the company’s stock valued at $2,673,000 after purchasing an additional 11,429 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president owned 41,048 shares of the company’s stock, valued at approximately $2,706,294.64. The trade was a 2.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 2,000 shares of company stock valued at $125,930 in the last 90 days. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Trading Up 0.8%

Prestige Consumer Healthcare stock opened at $69.36 on Thursday. Prestige Consumer Healthcare Inc. has a 52 week low of $57.25 and a 52 week high of $90.04. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11. The firm has a market capitalization of $3.28 billion, a PE ratio of 18.35, a PEG ratio of 2.16 and a beta of 0.43. The business’s 50-day simple moving average is $64.95 and its 200-day simple moving average is $63.40.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on PBH shares. Jefferies Financial Group lowered their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).